Blue Shield of Calif. is bypassing traditional pharmacy benefit managers to bring a Humira-referenced biosimilar, Idacio, to ...

Though we’ve recently observed some improvement in U.S. biosimilar penetration, market entry and uptake still consistently ...

Their discoveries have already led to the departure of a Stanford president, sparked charges from the Department of Justice, ...

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...

When patents for name brand medicines expire, the price of that medicine drops significantly as generic versions enter the market, but that process can take a while.

Cigna reported a strong quarterly performance, driven by specialty drugs and new clients for its pharmacy unit. Despite challenges in the Medicare Advantage market, Cigna expects at least 10% profit ...

AbbVie’s Humira missed Wall Street’s expectations in the third quarter but Skyrizi and Rinvoq’s continuing outperformance ...

在最近的财报电话会议上，艾伯维公司(ABBV)报告了2024年强劲的第三季度业绩，销售额超出预期，关键产品领域实现显著增长。首席执行官Rob Michael强调了公司非Humira产品的强劲表现，特别是Skyrizi和Rinvoq，预计这两款产品的销售额将超过170亿美元，超过初始预期。 这一表现促使艾伯维公司提高了全年收入和盈利指引。尽管由于生物仿制药竞争导致Humira销售下滑，但公司在免疫学 ...

AbbVie Inc (ABBV) reports robust sales growth driven by Skyrizi and Rinvoq, raises full-year guidance, and announces a 5.8% ...

The drug maker is leaning on medicines like Rinvoq and Skyrizi to offset declining sales of Humira, its former flagship ...

AbbVie stock jumped Wednesday after the pharma behemoth's new king in immunology finally outpaced its grandfather drug, Humira.